

Drug Utilization Review (DUR) Meeting Minutes

December 7, 2016

Members Present: Tanya Schmidt, Laura Schield, Russ Sobotta, Peter Woodrow, Andrea Honeyman, Michael Booth, LeNeika Roehrich

Members Absent: Katie Kram, Wendy Brown, Jeffrey Hostetter, Carlotta McCleary, Gaylord Kavlie, Zach Marty, James Carlson, Michael Quast

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

Old Business

P. Woodrow served as Chair in the absence of W. Brown, and called the meeting to order at 1:00 p.m. Chair P. Woodrow asked for a motion to approve the minutes of the September meeting. L. Roehrich moved that the minutes be approved and G. Betting seconded the motion. Chair P. Woodrow called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Second Reviews

A motion and second was made at the September meeting to place Namenda XR, Dihydroergotamine, Tetracycline, Spiriva Respimat 2.5 mcg, ophthalmic corticosteroids, and erythropoiesis-stimulating agents on prior authorization. The topics were brought up for a second review. The motion to place Namenda XR, Dihydroergotamine, Tetracycline, Spiriva Respimat 2.5 mcg, ophthalmic corticosteroids, and erythropoiesis-stimulating agents on prior authorization passed with no audible dissent.

PDL Update

B. Joyce shared with the Board all of the recommended PDL changes since the last 2016 version of the PDL posted. R. Troxell, representing Novartis, inquired about the criteria used to determine PDL status. R. Troxell also inquired about timeframe to address/discuss changes with DUR Board members before implementation in January. B. Joyce responded to questions.

Annual Prior Authorization Review of Forms and Criteria

The Board reviewed all forms and criteria that have previously been placed on prior authorization. Kelly Spielman, representing Merck, presented product information regarding Belsomra. B. Joyce spoke regarding an email from K. Kram asking if the narcotic/APAP form was still needed. B. Joyce said that the request would be reviewed. No changes were recommended during the review of the forms and criteria.

New Business

Synagis

B. Joyce shared with the Board the decision to move the handling of Synagis prior authorizations and claims over to the Medical management, therefore Synagis will not be covered under Pharmacy management.

Narcan Nasal Spray

B. Joyce shared with the Board the decision to not require Prior Authorization for the first (initial) fill of Narcan Nasal Sprays. Subsequent fills will require a prior authorization, but not initial.

Hepatitis C Update

A. Murphy reviewed changes in Hepatitis C criteria and updated Board members on utilization of treatments Medicaid covered this year.

Prednisolone ODT

B. Joyce reviewed prednisolone ODT with the Board. A motion was made by L. Roehrich to manage the class through prior authorization. The motion was seconded by P. Woodrow. This topic will be reviewed at the next meeting.

Metformin OSM

B. Joyce reviewed metformin OSM with the Board. A motion was made by T. Schmidt to manage the class through prior authorization. The motion was seconded by M. Booth. This topic will be reviewed at the next meeting.

Oral Testosterone

B. Joyce reviewed oral testosterone with the Board. A motion was made by L. Schield to manage the class through prior authorization. The motion was seconded by L. Roehrich. This topic will be reviewed at the next meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. M. Booth moved to approve the new criteria and A. Honeyman seconded the motion. P. Woodrow called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held March 1, 2017 at the Heritage Center in Bismarck. P. Woodrow made a motion to adjourn the meeting. M. Booth seconded. The motion passed with no audible dissent. P. Woodrow adjourned the meeting.